Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Circulation. 2022 Apr 12;145(15):e811-e838. doi: 10.1161/CIR.0000000000001056. Epub 2022 Mar 7.

Abstract

In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.

Keywords: AHA Scientific Statements; cardiovascular system; drug interactions; medical oncology; pharmacokinetics; pharmacology.

Publication types

  • Review

MeSH terms

  • American Heart Association
  • Cardiology*
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Humans
  • Medical Oncology
  • Neoplasms* / drug therapy
  • United States